Skip to main content
Defiance International

Published study records

Study records.

Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.

Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.

Study record counts

68,366 study records.

407 evidence-verified · 10,493 citation-verified · 57,416 identifier-confirmed · 50 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • Human research: 689
  • In vitro: 2,868
  • In vivo/preclinical: 3,719
  • Review/meta-analysis: 3,624
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2024

Thymosin β4 promotes zebrafish Mauthner axon regeneration by facilitating actin polymerization through binding to G-actin.

BMC biology · 2024

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2024

Effects of the Tobacco Defensin NaD1 Against Susceptible and Resistant Strains of Candida albicans.

Pathogens (Basel, Switzerland) · 2024

Study scale: Not reported in the declared source.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Limitations and uncertainty

Not reported in the declared source.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2024

Comparing the biological activity and composition of Cerebrolysin with other peptide preparations.

Journal of medicine and life · 2024

Study scale: Not reported in the declared source.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Vasoactive intestinal peptide exerts therapeutic action by regulating PTEN in a model of Sjögren's disease.

Immunity, inflammation and disease · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.

Metabolic brain disease · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2023

Mitochondrial stress and mitokines in aging.

Aging cell · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2023

MOTS-c Functionally Prevents Metabolic Disorders.

Metabolites · 2023

Study scale: Not reported in the declared source.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Thymosin beta-4 - A potential tool in healing middle ear lesions in adult mammals.

International immunopharmacology · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Development of the aganglionic colon following surgical rescue in a cell therapy model of Hirschsprung disease in rat.

Disease models & mechanisms · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Evidence of natural selection in the mitochondrial-derived peptides humanin and SHLP6.

Scientific reports · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2023

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.

Frontiers in endocrinology · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2023

Insight into the Mechanism of Interactions between the LL-37 Peptide and Model Membranes of Legionella gormanii Bacteria.

International journal of molecular sciences · 2023

Study scale: Not reported in the declared source.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Limitations and uncertainty

Not reported in the declared source.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.